Moderna shares are trading higher. The stock may be experiencing continued strength after the company, on Monday, reported results from its Phase 3 efficacy study evaluating its mRNA-1010 seasonal influenza vaccine in adults.
Moderna 與阿斯利康(AstraZeneca)、默克(Merck)和 Vertex Pharmaceuticals 等公司、國防高階研究計劃局(Defense Advanced Research Projects Agency)、生物醫學高級研究與發展局(Biomedical Advanced Research and Development Authority)和比爾及梅林達蓋茨基金會(Bill&Melinda Gates Foundation)都有策略合作。